Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple
 sclerosis (MS) patients.

 During the study patients will undergo a 3 dimensional gait analysis before starting
 treatment with glatiramer acetate and after 1 year of treatment.
Patients with a definite diagnosis of relapsing remitting multiple sclerosis (MS) will
 undergo a 3 dimensional gait analysis before initiation of treatment with glatiramer acetate.
 The gait analysis will include kinematic evaluation using a Charnwood Dynamics CODA CX-1
 system, 4 AMTI force plates and a Noraxon telemetric EMG system. Patients will be videotaped
 and will also undergo a detailed physical examination by a physical therapist.

 Treatment with Glatiramer acetate will be initiated after the gait analysis. Therapy will be
 observed and controlled by a neurologist fromn the staff of the Multiple Sclerosis Center.

 Repeat gait analysis will be performed after one year of treatment.
Inclusion Criteria:

 -  Clinical diagnosis of multiple sclerosis

 -  EDSS less than 5.5

 -  No cognitive disability

 Exclusion Criteria:

 -  EDSS over 5.5

 -  Inability to cooperate with gait analysis